New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
15:37 EDTULTI, AXS, EW, CHRW, AMP, HI, ATO, JKHY, CVD, MAC, CERN, AFL, GIMO, DV, HAIN, DATA, GNW, UNM, EQR, GILD, XOOM, BWLDNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Gilead Sciences (GILD), consensus 50c; AFLAC (AFL), consensus $1.39; Ameriprise Financial (AMP), consensus $1.81; Equity Residential (EQR), consensus 69c; Cerner (CERN), consensus 39c; CH Robinson Worldwide (CHRW), consensus 68c; Unum Group (UNM), consensus 84c; Macerich (MAC), consensus 92c; Edwards Lifesciences (EW), consensus 71c; Genworth Financial (GNW), consensus 30c; Covance (CVD), consensus 84c; AXIS Capital (AXS), consensus $1.47; Tableau Software (DATA), consensus 0c; Jack Henry & Associates (JKHY), consensus 60c; Ultimate Software (ULTI), consensus 41c; Hain Celestial (HAIN), consensus 87c; Atmos Energy (ATO), consensus 86c; Buffalo Wild Wings (BWLD), consensus $1.07; DeVry (DV), consensus 73c; Hillenbrand (HI), consensus 52c; Xoom (XOOM), consensus (1c); Gigamon (GIMO), consensus 12c.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>
January 27, 2016
16:25 EDTAMPAmeriprise reports Q4 operating EPS $2.47, consensus $2.35
Reports Q4 operating net revenue $3B, consensus $3B.
13:31 EDTDVDeVry to 'vigorously contest' FTC complaint
DeVry Education announced that it intends to "vigorously contest" a complaint filed by the Federal Trade Commission challenging the employment and earnings outcomes of DeVry University graduates. DeVry Group also learned that the Department of Education has taken an administrative action related more narrowly to certain DeVry University records for the period 1975 to 1983. "We intend to request a hearing on the Department's decision, and will collaborate closely with the Department to demonstrate our compliance and resolve this matter satisfactorily. DeVry Group believes that the FTC's complaint - filed 40 years after DeVry University began publishing accurate graduate employment statistics - is without a valid legal basis...DeVry Group has sought to fully cooperate with the FTC staff throughout the FTC's 24-month inquiry, and has provided extensive documentation disproving the FTC's claims and demonstrating the value of a DeVry University education. Despite this compelling evidence, a fully satisfactory resolution could not be reached," the company stated. DeVry shares remain down over 15% in afternoon trading.
12:34 EDTDVDeVry Education puts active after Federal Trade Commission filed suit
Subscribe for More Information
12:28 EDTDVFor-profit education names fall after FTC sues DeVry over marketing
DeVry Education (DV) and its peers in the for-profit education space are falling after the Federal Trade Commission filed suit against the company, alleging that DeVry's advertisements "deceived" consumers about the likelihood of finding jobs in their chosen fields of study and earning more than graduates from other universities. In a related action, the Department of Education is also moving against the company for those same practices, requiring it to stop the allegedly deceptive advertisements and take steps to ensure it can verify the truthfulness of its post-graduation employment outcomes, including hiring an independent auditor and informing students of its "unsubstantiated" statistics. The Department's action comes after its investigation of DeVry found the postgraduation employment claims "have not been substantiated to the extent required by law." PRICE ACTION: Shares of DeVry crashed 13.5% to $20.54 following the news, while Apollo Education (APOL), ITT Educational (ESI) and Strayer Education (STRA) each slid over 2% and Bridgepoint (BPI) fell 1%.
12:20 EDTDVEducation Department sends notice to DeVry University over representations
Subscribe for More Information
12:08 EDTDVDeVry sinks 19%, halted for volatility after FTC enforcement action
Subscribe for More Information
12:07 EDTDVDeVry sinks 19% after FTC brings enforcement action
Peers Apollo Education (APOL), Strayer (STRA), Grand Canyon (LOPE) and Bridgepoint Education (BPI) are also moving lower.
12:05 EDTDVFTC brings enforcement action against DeVry University
The Federal Trade Commission has filed suit against the operators of DeVry University, alleging that DeVry's advertisements "deceived consumers about the likelihood that students would find jobs in their fields of study, and would earn more than those graduating with bachelor's degrees from other colleges or universities." In its complaint, the FTC alleges that the defendants' claim that 90% of DeVry graduates actively seeking employment landed jobs in their field within six months of graduation was deceptive. The complaint charges that another key claim made by DeVry, that its graduates had 15% higher incomes one year after graduation on average than the graduates of all other colleges or universities, also was deceptive. In a related action, the U.S. Department of Education is also taking action against DeVry for its marketing practices, the FTC noted in its statement. The Department of Education is providing notice to DeVry that it will be requiring the institution both to stop certain advertising regarding the post-graduation employment outcomes of its students and to take additional steps to ensure that DeVry can substantiate the truthfulness of its post-graduation employment outcomes. The FTC Commission vote authorizing the staff to file the complaint was 4-0. The complaint was filed in the U.S. District Court for the Central District of California.
12:03 EDTDVFTC drings enforcement action against DeVry University
Subscribe for More Information
11:07 EDTGILDGilead sinks as Attorney General probes pricing strategy
Shares of drugmaker Gilead (GILD) are underperforming after Massachusetts Attorney General Maura Healey warned that her office may bring an unfair commercial conduct complaint against it related to the pricing for its Hepatitis C virus treatments Sovaldi and Harvoni. UNFAIR PRICING: Healey, in a letter addressed to Gilead CEO John Martin dated January 22 that has just been made public, said that her office is considering whether Gilead's pricing strategy for Sovaldi and Harvoni may constitute an "unfair trade practice" in violation of Massachusetts law. "Because Gilead's drugs offer a cure for a serious and life-threatening infectious disease, pricing the treatment in a manner that effectively allows HCV to continue spreading through vulnerable populations, as opposed to eradicating the disease altogether, results in massive public harm," Healey stated in her letter to Martin. Healey, who urged Gilead to adjust its pricing strategy, noted that the company has invoked the high cost and risk associated with research and development as a justification for its prices, but she said that Gilead quickly recouped its outlay to acquire Pharmasset by selling "$12.4B worth of HCV medication in the first year alone" after its deal. The AG, who said that Sovaldi costs $1,000 per pill in the U.S. but only $10 per pill in Egypt and about $4 per pill in India, contends that American taxpayers "have been footing the bill for Gilead's record profits." FREQUENT TARGET: The pricing of Gilead's hep C treatments have been the focus of significant criticism and political rhetoric in the past. In December, Senate Finance Committee Ranking Member Ron Wyden and senior committee member Chuck Grassley released the results of an 18-month investigation into the pricing and marketing of Sovaldi and Harvoni. The company "pursued a marketing strategy and final wholesale price of Sovaldi - $1,000 per pill, or $84,000 for a single course of treatment - that it believed would maximize revenue," and "fostering broad, affordable access was not a key consideration in the process of setting the wholesale prices," the senators wrote. Members of the Affordable Drug Pricing Task Force, who held a press conference last November to announce "meaningful action" to combat the "skyrocketing" costs of pharmaceuticals, specifically took aim at Sovaldi. During her campaigning efforts, presidential candidate Hillary Clinton has repeatedly decried the "outrageous" prices of specialty drugs. OTHERS TO WATCH: AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) also market or are at work on therapies for hepatitis C. PRICE ACTION: In morning trading, Gilead slid 2% to $90.35.
10:38 EDTGILDGilead trades near session lows
Subscribe for More Information
10:00 EDTBWLDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BG Group (BRGYY) downgraded to Neutral from Outperform at Credit Suisse... Bed Bath & Beyond (BBBY) downgraded to Sell from Neutral at Citi... Bill Barrett (BBG) downgraded to Neutral from Buy at Ladenburg... Brown & Brown (BRO) downgraded to Underweight at Morgan Stanley... Buffalo Wild Wings (BWLD) downgraded to Neutral from Buy at BTIG... Canadian National (CNI) downgraded to Market Perform from Outperform at Raymond James... DreamWorks (DWA) downgraded to Sell from Hold at Topeka... FirstMerit (FMER) downgraded at RBC Capital... Gentex (GNTX) downgraded to Neutral from Outperform at Baird... Haverty Furniture (HVT) downgraded to Sector Weight from Overweight at KeyBanc... Hercules Technology (HTGC) downgraded to Neutral from Buy at Compass Point... Horizon Technology (HRZN) downgraded to Market Perform from Outperform at Raymond James... Installed Building downgraded to Sector Weight from Overweight at KeyBanc... Jarden (JAH) downgraded to Neutral from Buy at Citi... K+S (KPLUF) downgraded to Sell from Hold at Berenberg... La-Z-Boy (LZB) downgraded at BB&T... Legacy Reserves (LGCY) downgraded to Market Perform from Outperform at FBR Capital... Medivation (MDVN) downgraded to Hold from Buy at Canaccord... Merck (MRK) downgraded to Neutral from Buy at BofA/Merrill... Metaldyne Performance (MPG) downgraded to Neutral from Outperform at Baird... Pier 1 Imports (PIR) downgraded to Sector Weight from Overweight at KeyBanc... Priceline (PCLN) downgraded to Neutral from Buy at Goldman... Profire Energy (PFIE) downgraded to Neutral from Buy at Chardan... Regeneron (REGN) downgraded to Hold at Canaccord... Starwood (HOT) downgraded to Underperform from Outperform at CLSA... Swiss Re (SSREY) downgraded to Equal Weight from Overweight at Morgan Stanley... TSYS (TSS) downgraded to Equal-Weight from Overweight at First Analysis... Talmer Bancorp (TLMR) downgraded to Sector Perform from Outperform at RBC Capital... TopBuild (BLD) downgraded to Sector Weight from Overweight at KeyBanc... TripAdvisor (TRIP) downgraded to Sell from Neutral at Goldman... VMware (VMW) downgraded to Hold from Buy at Summit Research... W.R. Grace (GRA) downgraded to Buy from Conviction Buy at Goldman... WEC Energy (WEC) downgraded to Neutral from Conviction Buy at Goldman... Welltower (HCN) downgraded to Underperform from Market Perform at BMO Capital... Yamana Gold (AUY) downgraded to Neutral from Overweight at JPMorgan.
08:52 EDTGILDMassachusetts AG warns Gilead hep C drug prices may be unfair, Boston Globe says
Subscribe for More Information
08:51 EDTEQREquity Residential closes sale of 23,262 apartment units for $5.365B
Equity Residential announced the closing of the sale, for $5.365B, of 72 properties, consisting of 23,262 apartment units that it had agreed to sell to controlled affiliates of Starwood Capital Group, as previously announced on October 26, 2015. The sale of 71 of the properties closed on January 26, 2016 and the company expects the final property sale to close later today.
07:09 EDTCERNCerner continues to take market share in HCIT, says Oppenheimer
Subscribe for More Information
06:45 EDTBWLDBuffalo Wild Wings downgraded to Neutral from Buy at BTIG
BTIG analyst Peter Saleh downgraded Buffalo Wild Wings to Neutral saying he believes domestic unit growth is slowing, the shifting sports calendar could impact same-store-sales growth in the coming quarters, and 2016 consensus expectations look too high. Additionally, the analyst believes uncertain sales trends and higher wing prices are a risk to this year's earnings growth, while slowing domestic unit growth longer-term and competitive factors could pressure growth rates and valuation.
January 26, 2016
15:53 EDTGILDGilead mentioned positively ahead of earnings at Barclays
Subscribe for More Information
09:55 EDTCERNLeerink /healthcare tech analysts hold analyst/industry conference call
Subscribe for More Information
08:06 EDTJKHYJack Henry's ProfitStar division adds RPM to ICBA
Subscribe for More Information
January 25, 2016
09:31 EDTAFLAflac upgraded to Buy from Hold at Sandler O'Neill
Sandler O'Neill upgraded Aflac to Buy and said its a high quality name in an uncertain environment.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use